Quick Links

Novel Method for Induction of Mucosal Immunity

Project Information
We are attempting to secure research funds to develop a new formulation for nasal vaccines. This formulation will facilitate antigen delivery to immune cells by temporarily disrupting nasal epithelial permeability barriers. We envisage utilizing our new formulation to develop a nasal vaccine against tuberculosis. Such a vaccine would be particularly useful in countering the entrance of tubercle bacilli into the human body by inhalation and subsequent establishment of lung infections.
Project Date: 
05/01/2010 to 05/01/2011
Type of Project: 
Research Area: 
Health Research
Sub-Research Area: 
Funding Source: 
Other Funding Source: 
We have yet to secure funding for this project.
McGill University Project Leader Information
Project Leader: 

Orest Blaschuk

Profile Picture: 
Primary Position
Faculty of Medicine
McGill University Health Centre (MUHC)
Research Interests: 
My research is focused on a group of cell adhesion molecules, known as cadherins. In particular, I am developing cadherin antagonists for use in the treatment of a wide variety of diseases. One of these antagonists (designated ADH1) was recently given orphan drug status by the FDA for the treatment of melanoma.

Graduate Studies :

Ph.D. Biochemistry (1984), University of Toronto
“Purification and Characterization of a Cell Aggregating Factor (Clusterin) from Ram Rete Testis Fluid”

Postdoctoral Studies :

Dept. of Biology (1984-1986), Princeton University

Grants Currently Held :

Adherex Technol. Inc.

Selected Publications: 
Principal Investigator